Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "CAS"

1713 News Found

Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi
People | September 16, 2025

Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi

Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,


MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025
News | September 16, 2025

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem


Kerala to host Ayush Mission workshop on “IT solutions in the Ayush sector”
News | September 16, 2025

Kerala to host Ayush Mission workshop on “IT solutions in the Ayush sector”

The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,


FDA launches crackdown on deceptive drug advertising
Policy | September 16, 2025

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole


Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
Healthcare | September 14, 2025

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025


Aarti Drugs receives order from MPCB for closure of process at Tarapur unit
News | September 12, 2025

Aarti Drugs receives order from MPCB for closure of process at Tarapur unit

The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system


Novartis to acquire Tourmaline Bio for $1.4 billion
News | September 10, 2025

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease


Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
Clinical Trials | September 06, 2025

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country